BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
CIA-Linked Investor Helped Quantum Systems Expand in US 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Toyota Global Sales Fall as China Demand Slumps 
Add as a preferred source on Google
REDWOOD CITY, Calif., April 03, 2018 -- ARMO BioSciences, Inc. (Nasdaq:ARMO), a late-stage immuno-oncology company, today announced that Martin Oft, M.D., Senior Vice President, Translational Medicine and Co-Founder, will participate in a panel presentation at the 8th Annual Cancer Immunotherapy Conference, taking place April 4-5 in New York City.
| Presentation Details: | ||||||||||||
| Date: | Wednesday, April 4 | |||||||||||
| Time: | 11:35am Eastern Time | |||||||||||
| Location: | Apella Event Space Alexandria Center, New York City | |||||||||||
| Topic: | Cytokines | |||||||||||
| Panelists: | Martin Oft, M.D., Senior Vice President, Translational Medicine and Co-Founder | |||||||||||
| ARMO BioSciences, Inc. | ||||||||||||
| Deborah Charych, Ph.D., Executive Director of Research & Development | ||||||||||||
| Nektar Therapeutics | ||||||||||||
About the 8th Annual Cancer Immunotherapy Conference
Hosted by William Blair and MaidStone Life Sciences, the annual cancer immunotherapy conference is a unique, two-day conference that brings together the founding scientists, leading clinicians, and pioneering biopharmaceutical companies driving the field of cancer immunotherapy. The agenda is designed to facilitate the exchange of information and highlight potential areas of opportunity for executives, investors, and others involved in transforming the future of cancer treatments. Each day will consist of a series of presentations from leading experts across the various disciplines in immuno-oncology followed by panel discussions to further elucidate key issues and paths forward.
About ARMO BioSciences
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. The Company’s lead product candidate, AM0010 (pegilodecakin, PEGylated Interleukin-10), has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types. The drug is currently being investigated in a Phase 3 randomized pivotal clinical trial in pancreatic cancer patients. ARMO also has a number of other immuno-oncology product candidates in various stages of pre-clinical development including: AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, form of recombinant human Interleukin-15 (IL-15); and AM0012, a form of recombinant human Interleukin-12 (IL-12). For more information, please visit www.armobio.com.
CONTACTS:
ARMO BioSciences, Inc.
Herb Cross, Chief Financial Officer
650-241-3993
[email protected]
Dan Ferry
LifeSci Advisors, LLC
617-535-7746
